ARTICLE | Clinical News

DBV's peanut allergy therapy meets Phase III safety endpoint

December 8, 2017 9:00 PM UTC

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Viaskin Peanut (DBV-712) met the primary safety endpoint in the Phase III REALISE trial to treat peanut allergy in patients ages 4-11. Specifically, Viaskin Peanut was well tolerated with no new or unexpected adverse events reported. The most common adverse events reported were mild and moderate local application-site reactions.

The double-blind, placebo-controlled, North American trial evaluated a once-daily 250 μg dose of Viaskin Peanut for 6 months in 393 patients with physician-diagnosed peanut allergy. Secondary endpoints in the trial include changes in peanut-specific IgE and IgG4 levels and patient-reported scores on the Food Allergy Quality of Life Questionnaire (FAQLQ) and the Food Allergy Independent Measure (FAIM). Patients will continue receiving treatment for up to 36 months in an open-label extension...

BCIQ Company Profiles

DBV Technologies S.A.